HzFhS Rossbacher-Spickermann eGbR
- Address
- Frankfurter Allee 100, Friedrichshain, 10247 Berlin, Germany
Skin and Connective Tissue Diseases
At HzFhS Rossbacher-Spickermann eGbR in Berlin, the clinical research focus is centered on skin and connective tissue diseases, especially atopic dermatitis and related inflammatory conditions. The studies are designed to assess how well new and existing treatments work, while also looking closely at safety and tolerability for people living with chronic skin disease.
- Evaluation of a new topical treatment for mild to moderate atopic dermatitis, compared with an approved therapy and a non-active formulation, to better understand treatment benefit.
- Research on nummular dermatitis and nummular eczema to test whether a targeted therapy can improve disease control in adults.
This small but focused program reflects a practical interest in improving care for common inflammatory dermatologic conditions through better symptom control and treatment effectiveness.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Almirall S.A.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in HzFhS Rossbacher-Spickermann eGbR
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of Lebrikizumab in Adults With Nummular Dermatitis Inadequately Controlled by Topical Corticosteroids: A Phase 3, Randomized, Placebo-Controlled Study | Almirall S.A. | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lebrikizumab | 1 | Unknown | 2026-04-10 | 2026-04-10 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.